Abstract：
Psychedelic compounds, including psilocybin, LSD (lysergic acid diethylamide), DMT (N,N -dimethyltryptamine), and 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), all of which are serotonin 2A receptor agonists, are being investigated as potential treatments. This review aims to summarize the current clinical research on these 4 compounds and mescaline to guide future research. Their mechanism(s) of action, pharmacokinetics, pharmacodynamics, efficacy, and safety were reviewed. While evidence for therapeutic indications, with the exception of psilocybin for depression, is still relatively scarce, we noted no differences in psychedelic effects beyond effect duration. Therefore, it remains unclear whether different receptor profiles contribute to the therapeutic potential of these compounds. More research is needed to differentiate these compounds in order to inform which compounds might be best for different therapeutic uses.
摘要：
迷幻化合物,包括psilocybin,LSD,DMT,和5-MeO-DMT都是5-羟色胺（5-HT）2A受体激动剂，正在研究作为潜在的治疗方法。本综述旨在总结这四种化合物和美斯卡林的临床研究现状，以指导未来的研究。他们的作用机制，药代动力学，药效学,功效,和安全性进行了审查。虽然有治疗适应症的证据，除了psilocybin治疗抑郁症,仍然相对稀缺，我们注意到除了作用持续时间之外的迷幻作用没有差异。因此,尚不清楚不同的受体谱是否有助于这些化合物的治疗潜力。需要更多的研究来区分这些化合物，以告知哪些化合物可能最适合不同的治疗用途。
